KalVista Pharmaceuticals, Inc. (KALV) Announces Q3 Loss While Exceeding Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Source: NASDAQ.COM
Quarterly Performance: KalVista Pharmaceuticals reported a quarterly loss of $0.92 per share, slightly better than the expected loss of $0.96, with revenues of $13.69 million, significantly surpassing estimates by 242.30%.
Stock Outlook: The company's stock has increased by 27.3% since the start of the year, outperforming the S&P 500, but future performance will depend on management's commentary and earnings estimate revisions.
Earnings Estimates: Current consensus estimates for the next quarter are a loss of $0.85 per share on $12.8 million in revenues, while the fiscal year estimate is a loss of $2.94 on $16.9 million in revenues.
Industry Context: KalVista operates in the Medical - Drugs industry, which ranks in the top 37% of Zacks industries, indicating a favorable environment that could influence stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.770
Low
29.00
Averages
34.38
High
39.00
Current: 26.770
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea exercised 33,800 options and sold them for approximately $905,000 on May 27, 2026, reducing his direct holdings to 229,918 shares, indicating a potential lack of confidence in the company's future prospects.
- Buyout Proposal Impact: Yea sold shares at $26.78 each, while Chiesi Group's pending buyout offer stands at $27 per share, suggesting that Yea's decision to sell may have been hasty, potentially missing out on greater returns.
- Ekterly Market Potential: KalVista's Ekterly, launched in July 2025, achieved $49 million in sales last year, and if FDA approval extends its use to children aged 2 to 11, it could significantly boost market demand and address unmet medical needs.
- Financial Performance Warning: Despite Ekterly's strong initial performance, KalVista reported a loss of $109.5 million for the eight months ending December 31, 2025, highlighting challenges in profitability that may affect investor confidence moving forward.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, exercised 33,800 stock options and immediately sold them for approximately $905,000, indicating a short-term liquidity need for his shares.
- Holding Changes: Following this transaction, Yea holds 229,918 shares valued at about $6.16 million, and despite a 28.84% reduction in direct holdings over the past year, his selling behavior does not significantly increase long-term holding risks.
- Acquisition Context: Yea sold shares at $26.78 each while Chiesi Group has made a buyout offer at $27 per share, reflecting the market's assessment of KalVista's potential value amid acquisition talks.
- Product Market Outlook: KalVista's Ekterly drug, launched in July 2025, achieved $49 million in sales last year, and if approved for use in children aged 2 to 11 by the FDA, it is expected to drive further sales growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating KalVista Pharmaceuticals (NASDAQ:KALV) for potential violations of federal securities laws related to its sale to Chiesi Group for $27.00 per share in cash, indicating possible breaches of fiduciary duties to shareholders.
- Shareholder Rights: The firm encourages KalVista shareholders to reach out to discuss their rights and options, highlighting the potential financial disadvantages they may face compared to ordinary shareholders in the proposed transaction.
- Other Companies Under Scrutiny: The investigation also includes Global Business Travel Group (NYSE:GBTG) selling for $9.50 per share to Long Lake Management, Modiv Industrial (NYSE:MDV) merging with Global Net Lease, and Catalyst Pharmaceuticals (NASDAQ:CPRX) selling for $31.50 per share to Angelini Pharma S.p.A.
- Legal Support Offered: Halper Sadeh LLC aims to seek increased consideration, additional disclosures, and other relief on behalf of shareholders, demonstrating a commitment to protecting shareholder interests and rights throughout these transactions.
See More
Monteverde Law Firm Investigates Multiple M&A Transactions
- Shareholder Rights Investigation: Monteverde & Associates is investigating the transaction between Modiv Industrial, Inc. and Global Net Lease, Inc., where Modiv shareholders are expected to own approximately 11% of the combined entity, potentially impacting long-term shareholder returns.
- Cash Return Commitment: Shareholders of Global Business Travel Group, Inc. are expected to receive $9.50 per share in cash, which may provide immediate liquidity and enhance investor confidence in the transaction.
- Acquisition Price Transparency: KalVista Pharmaceuticals, Inc. shareholders are anticipated to receive $27.00 per share in cash, reflecting market recognition of the company and potentially attracting more investor interest.
- Merger Voting Arrangement: The merger plan between Legato Meger Corp. III and Einride AB is set for a shareholder vote on June 4, 2026, where shareholders will exchange each Legato ordinary share for Einride common stock, potentially affecting shareholder structure and future earnings.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and encouraging shareholders to explore their options.
- Acquisition Terms: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is being sold to Chiesi Group for $27.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration to ensure fair compensation for shareholders.
- Transaction Options: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., offering shareholders a choice between cash and stock combinations or $63.89 per share in cash, with Halper Sadeh LLC advocating for better terms on behalf of shareholders.
- Legal Support: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4.00 per share, and Halper Sadeh LLC provides no-cost legal consultations to help shareholders understand their rights and options, ensuring their legal interests are protected.
See More
Investigation Alerts for Multiple Company Mergers
- KalVista Merger Investigation: KalVista Pharmaceuticals is set to be acquired by Chiesi Group for $27.00 per share, implying a total value of approximately $1.9 billion, with investigations focusing on whether the board breached fiduciary duties by failing to conduct a fair process.
- Thermon Acquisition Review: Thermon Group Holdings will be acquired by CECO Environmental in a deal valued at around $2.2 billion, allowing shareholders to choose between cash and stock, with investigations into potential breaches of fiduciary duties by the board regarding fair treatment of shareholders.
- Sila Realty Acquisition Inquiry: Sila Realty Trust is to be acquired by Blue Owl Capital for $30.38 per share, totaling approximately $2.4 billion, with investigations examining whether the board failed to ensure a fair process and fair value for shareholders.
- Lisata Therapeutics Merger Scrutiny: Lisata Therapeutics will be acquired by Kuva Labs for $4.00 per share plus contingent value rights, with investigations into whether the board breached fiduciary duties by not ensuring fair value in the transaction for shareholders.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea exercised 33,800 options and sold them for approximately $905,000 on May 27, 2026, reducing his direct holdings to 229,918 shares, indicating a potential lack of confidence in the company's future prospects.
- Buyout Proposal Impact: Yea sold shares at $26.78 each, while Chiesi Group's pending buyout offer stands at $27 per share, suggesting that Yea's decision to sell may have been hasty, potentially missing out on greater returns.
- Ekterly Market Potential: KalVista's Ekterly, launched in July 2025, achieved $49 million in sales last year, and if FDA approval extends its use to children aged 2 to 11, it could significantly boost market demand and address unmet medical needs.
- Financial Performance Warning: Despite Ekterly's strong initial performance, KalVista reported a loss of $109.5 million for the eight months ending December 31, 2025, highlighting challenges in profitability that may affect investor confidence moving forward.
See More
KalVista Executive Sells Stock Options Amid Buyout Offer
- Transaction Overview: Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, exercised 33,800 stock options and immediately sold them for approximately $905,000, indicating a short-term liquidity need for his shares.
- Holding Changes: Following this transaction, Yea holds 229,918 shares valued at about $6.16 million, and despite a 28.84% reduction in direct holdings over the past year, his selling behavior does not significantly increase long-term holding risks.
- Acquisition Context: Yea sold shares at $26.78 each while Chiesi Group has made a buyout offer at $27 per share, reflecting the market's assessment of KalVista's potential value amid acquisition talks.
- Product Market Outlook: KalVista's Ekterly drug, launched in July 2025, achieved $49 million in sales last year, and if approved for use in children aged 2 to 11 by the FDA, it is expected to drive further sales growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating KalVista Pharmaceuticals (NASDAQ:KALV) for potential violations of federal securities laws related to its sale to Chiesi Group for $27.00 per share in cash, indicating possible breaches of fiduciary duties to shareholders.
- Shareholder Rights: The firm encourages KalVista shareholders to reach out to discuss their rights and options, highlighting the potential financial disadvantages they may face compared to ordinary shareholders in the proposed transaction.
- Other Companies Under Scrutiny: The investigation also includes Global Business Travel Group (NYSE:GBTG) selling for $9.50 per share to Long Lake Management, Modiv Industrial (NYSE:MDV) merging with Global Net Lease, and Catalyst Pharmaceuticals (NASDAQ:CPRX) selling for $31.50 per share to Angelini Pharma S.p.A.
- Legal Support Offered: Halper Sadeh LLC aims to seek increased consideration, additional disclosures, and other relief on behalf of shareholders, demonstrating a commitment to protecting shareholder interests and rights throughout these transactions.
See More
Monteverde Law Firm Investigates Multiple M&A Transactions
- Shareholder Rights Investigation: Monteverde & Associates is investigating the transaction between Modiv Industrial, Inc. and Global Net Lease, Inc., where Modiv shareholders are expected to own approximately 11% of the combined entity, potentially impacting long-term shareholder returns.
- Cash Return Commitment: Shareholders of Global Business Travel Group, Inc. are expected to receive $9.50 per share in cash, which may provide immediate liquidity and enhance investor confidence in the transaction.
- Acquisition Price Transparency: KalVista Pharmaceuticals, Inc. shareholders are anticipated to receive $27.00 per share in cash, reflecting market recognition of the company and potentially attracting more investor interest.
- Merger Voting Arrangement: The merger plan between Legato Meger Corp. III and Einride AB is set for a shareholder vote on June 4, 2026, where shareholders will exchange each Legato ordinary share for Einride common stock, potentially affecting shareholder structure and future earnings.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and encouraging shareholders to explore their options.
- Acquisition Terms: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is being sold to Chiesi Group for $27.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration to ensure fair compensation for shareholders.
- Transaction Options: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., offering shareholders a choice between cash and stock combinations or $63.89 per share in cash, with Halper Sadeh LLC advocating for better terms on behalf of shareholders.
- Legal Support: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4.00 per share, and Halper Sadeh LLC provides no-cost legal consultations to help shareholders understand their rights and options, ensuring their legal interests are protected.
See More
Investigation Alerts for Multiple Company Mergers
- KalVista Merger Investigation: KalVista Pharmaceuticals is set to be acquired by Chiesi Group for $27.00 per share, implying a total value of approximately $1.9 billion, with investigations focusing on whether the board breached fiduciary duties by failing to conduct a fair process.
- Thermon Acquisition Review: Thermon Group Holdings will be acquired by CECO Environmental in a deal valued at around $2.2 billion, allowing shareholders to choose between cash and stock, with investigations into potential breaches of fiduciary duties by the board regarding fair treatment of shareholders.
- Sila Realty Acquisition Inquiry: Sila Realty Trust is to be acquired by Blue Owl Capital for $30.38 per share, totaling approximately $2.4 billion, with investigations examining whether the board failed to ensure a fair process and fair value for shareholders.
- Lisata Therapeutics Merger Scrutiny: Lisata Therapeutics will be acquired by Kuva Labs for $4.00 per share plus contingent value rights, with investigations into whether the board breached fiduciary duties by not ensuring fair value in the transaction for shareholders.
See More
